PT3200828T - Composições intranasais para o tratamento de doenças e distúrbios neurológicos e neurodegenerativos - Google Patents
Composições intranasais para o tratamento de doenças e distúrbios neurológicos e neurodegenerativosInfo
- Publication number
- PT3200828T PT3200828T PT158481002T PT15848100T PT3200828T PT 3200828 T PT3200828 T PT 3200828T PT 158481002 T PT158481002 T PT 158481002T PT 15848100 T PT15848100 T PT 15848100T PT 3200828 T PT3200828 T PT 3200828T
- Authority
- PT
- Portugal
- Prior art keywords
- neurological
- disorders
- treatment
- neurodegenerative diseases
- intranasal compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014903944A AU2014903944A0 (en) | 2014-10-03 | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3200828T true PT3200828T (pt) | 2020-10-08 |
Family
ID=55629161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158481002T PT3200828T (pt) | 2014-10-03 | 2015-09-30 | Composições intranasais para o tratamento de doenças e distúrbios neurológicos e neurodegenerativos |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10471040B2 (pt) |
| EP (1) | EP3200828B1 (pt) |
| JP (3) | JP2017530195A (pt) |
| AU (1) | AU2015327762C1 (pt) |
| CA (1) | CA2961936C (pt) |
| DK (1) | DK3200828T3 (pt) |
| ES (1) | ES2822562T3 (pt) |
| HU (1) | HUE052441T2 (pt) |
| PL (1) | PL3200828T3 (pt) |
| PT (1) | PT3200828T (pt) |
| WO (1) | WO2016049700A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3200828T3 (da) * | 2014-10-03 | 2020-10-12 | Lachesis Biosciences Ltd | Intranasale sammensætninger til behandling af neurologiske og neurodegenerative sygdomme og forstyrrelser |
| RS60554B1 (sr) * | 2017-02-02 | 2020-08-31 | Otolanum Ag | Intranazalna kompozicija koja sadrži betahistin |
| AU2021297549A1 (en) * | 2020-06-25 | 2023-01-05 | Lachesis Biosciences Limited | Methods of treating or preventing organophosphorus poisoning |
| GB2614167A (en) * | 2020-10-01 | 2023-06-28 | Lyra Therapeutics Inc | Osmotic drug delivery implants |
| CN115919767B (zh) * | 2022-10-13 | 2023-08-11 | 暨南大学 | 卡巴拉汀鼻喷雾剂及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5733M (pt) | 1966-09-27 | 1968-01-22 | ||
| US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
| FR2722989B1 (fr) | 1994-07-29 | 1997-05-30 | Synthelabo | Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales |
| US6558560B2 (en) * | 2001-07-27 | 2003-05-06 | Hewlett-Packard Company | Method for the fabrication of electrical contacts |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20030225031A1 (en) * | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| US20080020018A1 (en) * | 2004-09-27 | 2008-01-24 | Joey Moodley | Combination Products |
| US8187570B1 (en) * | 2005-01-04 | 2012-05-29 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| CA2604052C (en) * | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of cns-related conditions |
| ATE544444T1 (de) * | 2005-10-11 | 2012-02-15 | Yissum Res Dev Co | Zusammensetzungen für die nasale abgabe |
| US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
| CA2641392A1 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| US20070202055A1 (en) * | 2006-02-09 | 2007-08-30 | Julianne Berry | Pharmaceutical Formulations |
| CN101784287B (zh) * | 2007-06-26 | 2013-04-24 | 若素制药株式会社 | 水性组合物 |
| FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
| DK3029039T3 (en) | 2010-05-17 | 2017-12-04 | Forum Pharmaceuticals Inc | PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE |
| US8673338B2 (en) * | 2011-07-29 | 2014-03-18 | Massachusetts Eye And Ear Infirmary | Methods of delivering pharmaceutical agents |
| DK3200828T3 (da) * | 2014-10-03 | 2020-10-12 | Lachesis Biosciences Ltd | Intranasale sammensætninger til behandling af neurologiske og neurodegenerative sygdomme og forstyrrelser |
-
2015
- 2015-09-30 DK DK15848100.2T patent/DK3200828T3/da active
- 2015-09-30 HU HUE15848100A patent/HUE052441T2/hu unknown
- 2015-09-30 PT PT158481002T patent/PT3200828T/pt unknown
- 2015-09-30 WO PCT/AU2015/050591 patent/WO2016049700A1/en active Application Filing
- 2015-09-30 PL PL15848100T patent/PL3200828T3/pl unknown
- 2015-09-30 ES ES15848100T patent/ES2822562T3/es active Active
- 2015-09-30 JP JP2017536991A patent/JP2017530195A/ja active Pending
- 2015-09-30 CA CA2961936A patent/CA2961936C/en active Active
- 2015-09-30 EP EP15848100.2A patent/EP3200828B1/en active Active
- 2015-09-30 US US15/516,233 patent/US10471040B2/en active Active
- 2015-09-30 AU AU2015327762A patent/AU2015327762C1/en active Active
-
2019
- 2019-09-13 US US16/569,986 patent/US10933045B2/en active Active
-
2020
- 2020-03-04 JP JP2020036966A patent/JP7357571B2/ja active Active
-
2021
- 2021-01-27 US US17/160,009 patent/US11911360B2/en active Active
- 2021-10-20 JP JP2021171712A patent/JP2022003100A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7357571B2 (ja) | 2023-10-06 |
| EP3200828A1 (en) | 2017-08-09 |
| AU2015327762C1 (en) | 2020-10-22 |
| ES2822562T3 (es) | 2021-05-04 |
| HUE052441T2 (hu) | 2021-04-28 |
| PL3200828T3 (pl) | 2021-01-25 |
| EP3200828A4 (en) | 2018-04-25 |
| CA2961936A1 (en) | 2016-04-07 |
| JP2022003100A (ja) | 2022-01-11 |
| EP3200828B1 (en) | 2020-08-12 |
| US10933045B2 (en) | 2021-03-02 |
| US20210145789A1 (en) | 2021-05-20 |
| AU2015327762B2 (en) | 2020-06-25 |
| CA2961936C (en) | 2023-03-14 |
| US10471040B2 (en) | 2019-11-12 |
| AU2015327762A1 (en) | 2017-04-20 |
| WO2016049700A1 (en) | 2016-04-07 |
| DK3200828T3 (da) | 2020-10-12 |
| US20200078331A1 (en) | 2020-03-12 |
| JP2017530195A (ja) | 2017-10-12 |
| US20170239209A1 (en) | 2017-08-24 |
| JP2020090547A (ja) | 2020-06-11 |
| US11911360B2 (en) | 2024-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
| IL304429A (en) | Methods and preparations for the treatment of epileptic disorders | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| IL264070A (en) | Methods and preparations for the treatment of disorders and diseases involving rdh12 | |
| ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
| GB201408387D0 (en) | Treatment of respiratory disorders | |
| PT3200828T (pt) | Composições intranasais para o tratamento de doenças e distúrbios neurológicos e neurodegenerativos | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| IL263080B (en) | Treatment of neurological disorders | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| GB201411616D0 (en) | Diagnosis and treatment of neurodegenerative disorders | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| AU2014903944A0 (en) | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders | |
| GB201704666D0 (en) | Treatment of neurodegenerative diseases | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders | |
| SG11201706952VA (en) | Compositions and methods for the treatment of epilepsy and neurological disorders |